This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?
Efficacy
Efficacy
Tegsedi significantly delays disease progression vs placebo(1)
Tegsedi significantly delays disease progression vs placebo1
Earlier initiation of Tegsedi demonstrated better outcomes in neuropathic progression2*
Tegsedi significantly stabilise neuropathy-related QoL vs placebo1,2
Tegsedi sustains neuropathy-related QoL stabilisation over 2 years1,2
Read more
References
mNIS+7: modified Neuropathy Impairment Score+7 composite score
*No statistical analysis performed
Tegsedi 284mg is the same as the study drug inotersen sodium 300mg. TTR: transthyretin; OLE: open label extension
- Tegsedi Summary of Product Characteristics. April 2021.
- Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.
- Brannagan TH, Wang AK, Coelho T, et al. Eur J Neurol. 2020;27(8):1374-1381. doi:10.1111/ene.14285
- Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20.
NEURO-TTR study design2
A phase 3, multi-centre, double-blind, randomised, placebo-controlled study. 15-month treatment period.
Patients
- Adults 18 to 82 years of age
- Stage 1 or stage 2 hATTR polyneuropathy
- Neuropathy Impairment Score ≥10 and ≤130;
Randomly assigned 2:1
- Tegsedi (284 mg weekly subcutaneous dose; n=112)
- Placebo (n=60)
Primary end points
- Change in mNIS+7 (range, -22.3 to 346.3, with higher scores indicating poorer function)
- Change in Norfolk QoL-DN questionnaire score (range, -4 to 136, with higher scores indicating poorer quality of life). A decrease in scores indicated improvement.
NEURO-TTR OLE study design3
Inclusion criteria
Satisfactory completion of treatment in NEURO-TTR.
Patient groups
Patients receiving Tegsedi in NEURO-TTR continued to receive Tegsedi (Tegsedi-Tegsedi group). Patients receiving placebo in NEURO-TTR switched to Tegsedi (placebo-Tegsedi group).
Administration
Patients received 284 mg Tegsedi once weekly via subcutaneous injection for up to 260 weeks (5 years).